What do pathology findings of pankeratin‑positive, thyroid transcription factor‑1 (TTF‑1)‑positive, napsin‑A‑positive, and p40‑negative neoplastic cells indicate regarding diagnosis and adequacy for molecular testing?

Metastatic Lung Adenocarcinoma with Adequate Tissue for Molecular Testing

These pathology results indicate metastatic lung adenocarcinoma, and the specimen contains sufficient tumor cells (>200) to proceed immediately with comprehensive molecular testing for targetable mutations including EGFR, ALK, ROS1, and other actionable drivers.

What This Immunohistochemical Profile Means

The immunostaining pattern is diagnostic for lung adenocarcinoma:

• Pankeratin positive: Confirms epithelial origin
• TTF-1 positive: Indicates lung or thyroid origin; sensitivity 75-80% for lung adenocarcinoma 1
• Napsin A positive: Highly specific for lung adenocarcinoma (better specificity than TTF-1 alone); expressed in type II pneumocytes 1
• P40 negative: Excludes squamous cell carcinoma (P40 has 98-100% specificity for squamous differentiation) 1

This combination has 86-96% sensitivity and 94-100% specificity for distinguishing lung adenocarcinoma from squamous cell carcinoma 1, 2, 3. The dual positivity of TTF-1 and napsin A is particularly robust, with studies showing 74% sensitivity and 87-96% specificity for lung adenocarcinoma 1.

Critical Next Step: Molecular Testing

You must proceed with molecular biomarker testing immediately because:

1. Adequate tissue is confirmed: The report explicitly states >200 tumor cells are available, which meets the threshold for molecular testing 4

2. Adenocarcinoma histology mandates testing: Current guidelines from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology require molecular testing for all lung adenocarcinomas to identify targetable mutations 4

3. Testing should include at minimum:

   • EGFR mutations
   • ALK rearrangements
   • ROS1 rearrangements
   • Consider comprehensive next-generation sequencing panels for additional actionable targets (BRAF, MET, RET, KRAS G12C, NTRK, HER2)

Important Caveats

Potential diagnostic pitfalls to consider:

• Napsin A is also expressed in renal cell carcinoma: However, the combination with TTF-1 positivity strongly favors lung origin over kidney 1

• TTF-1 can be positive in thyroid carcinoma: But thyroid tumors are napsin A negative, so the dual positivity confirms pulmonary origin 1

• Poorly differentiated adenocarcinomas may have reduced TTF-1/napsin A expression: Your case shows "strong and diffuse" staining, suggesting moderate to well-differentiated tumor 1

• Non-specific staining can occur: TTF-1 may stain alveolar macrophages; napsin A may stain normal type II pneumocytes. The pathologist has already accounted for this by confirming neoplastic cell staining 1

Clinical Implications for Treatment

The identification of lung adenocarcinoma origin directly impacts treatment selection:

• Targeted therapy eligibility: If molecular testing identifies EGFR mutations, ALK/ROS1 rearrangements, or other actionable drivers, targeted tyrosine kinase inhibitors are first-line therapy and significantly improve progression-free survival and quality of life compared to chemotherapy 4

• Immunotherapy considerations: PD-L1 testing should also be performed if not already done, as this influences immunotherapy selection

• Squamous-sparing regimens avoided: The negative P40 confirms this is NOT squamous cell carcinoma, so you can use adenocarcinoma-appropriate regimens without restriction 4

The pathologist has done the critical work of confirming both diagnosis and tissue adequacy—your immediate action is to ensure molecular testing is ordered and results are obtained before initiating systemic therapy.